E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with end-stage pulmonary failure, who are receiving a primary single or double pulmonary allograft |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to assess the efficacy and safety of EZ-2053 9 mg/kg as compared to placebo for prophylaxis of acute pulmonary allograft rejection in adult recipients of a primary pulmonary allograft. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- ≥ 18 years of age - Recipient of a primary single or double pulmonary allograft - Capable of understanding the purposes and risks of the study and has given written informed consent, and agrees to comply with the study requirements - Women of childbearing potential must have a negative serum pregnancy test within 4 days prior to randomization
|
|
E.4 | Principal exclusion criteria |
- Prior plasma exchange and/or treatment with IVIg within the past 5 years - Pulmonary infection with pan-resistant Pseudomonas or any Burkholderia species - Known positive blood cultures - Undergoing second or living donor transplant - Donor lung ischemia time >8 hours - Previously received or is receiving a multi-organ transplant - Pregnant women, nursing mothers or women of child-bearing potential who are unwilling to use reliable contraception. Effective contraception must be used BEFORE beginning study drug therapy, for the duration of the study and for 6 weeks following completion of the study - Active, extra pulmonary systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of a chronic active hepatitis B or C - Active liver disease (liver function tests ≥ 2 times upper normal limit) - Severe anemia (hemoglobin, < 6 g/dL), leukopenia (WBC < 2500/mm3), thrombocytopenia (platelet count < 80,000/ mm3), polycythemia (Hct > 54% [male], Hct > 49% [female]) or clinically significant coagulopathy - Recipient or donor is seropositive for human immunodeficiency virus (HIV) - Previous exposure or known contraindication to administration of EZ-2053 or rabbit proteins - Current malignancy or a history of malignancy (within the previous 5 years), except non-metastatic basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully - Unstable cardiovascular disease or myocardial infarction within the previous 6 months - Currently participating in another clinical trial with an investigational agent and/or is taking or has been taking an investigational drug in the 30 days prior to transplant and/or has not recovered from any reversible side effects of prior investigational drug - Unlikely to comply with visits schedule in the protocol - Any current or history of substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator
Postoperatively, but prior to randomization, patients with any of the following will be excluded: - Failure to document two measurements of PaO2/FiO2 >200mmHg, separated by 3 hours (+/- 1 hour), with the last measurement within 2 hours of randomization Note: for patients on a nasal cannula, estimate the FiO2 as 4% over 21% for each L/min. For example, 2 L/min = 21 %+ (2 x 4%) = 29%. - Need for extracorporeal membrane oxygenation - Uncontrolled bleeding - Frank evidence of cardiopulmonary instability and/or a patient, who in the estimation of the transplant team, is at high risk for death - Known positive blood culture (any pending microbiology tests should be reviewed prior to randomization) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy failure between placebo and 9 mg/kg EZ-2053 at 12 months post-transplant. Efficacy failure is defined as the first occurrence of death, graft loss, acute rejection (as defined in Section 10.1) and/or loss to follow-up. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |